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ABSTRACT  
 
The Hedgehog (Hh) receptor Patched1 (PTCH1) is a well-known tumor suppressor 
that in its active form represses Smoothened (SMO) activity, inhibits proliferation, 
and induces apoptosis. The cytoplasmic C-terminal domain (CTD) regulates 
PTCH1 turnover and nucleates a pro-apoptotic complex. In this study, it was 
mechanistically determined that Autophagy Related 10 (ATG101), essential for 
mammalian autophagy, physically interacts with the CTD of PTCH1 and connects 
it to the ULK complex, which stimulates the autophagy machinery in response to 
changes in nutrient availability. This interaction results in a blockade of basal 
autophagic flux and accumulation of autophagosomes with undegraded cargo. 
Remarkably, this function of PTCH1 is independent of its repressive activity on 
SMO, as shown in SMO-deficient cells or in the presence of a SMO inhibitor, but 
is opposed by Sonic Hedgehog (SHH). These findings reveal a novel non-
canonical function of PTCH1 that limits autophagy, mediated by ATG101, which 
could have therapeutic implications in Hh-dependent cancers. 
 
IMPLICATIONS 
Loss-of-function of the tumor suppressor Patched1 might promote cancer cell 
fitness by increasing autophagic flux in response to metabolic or environmental 
stresses.  
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INTRODUCTION 
The Hedgehog (HH) signaling pathway has essential functions in embryonic 
patterning, including cell fate specification, axon guidance, angiogenesis, and cell 
proliferation and survival (1, 2). Dysregulated activation of the HH pathway after 
birth can originate and/or promote cancer growth in many tissue types (3). The Hh 
ligands, Sonic, Indian, and Desert HH (SHH, IHH, DHH), bind to two closely related 
receptors, Patched1 and Patched2 (PTCH1 and PTCH2) (4, 5). In the absence of 
ligands, PTCH proteins repress Smoothened (SMO), a G protein-coupled-receptor 
superfamily member (6-8). Full activation of SMO occurs when HH ligands bind to 
and inhibit PTCH1/2 resulting in retention of SMO at the primary cilium and 
activation of GLI-dependent transcription, known as canonical HH signaling (5).  
PTCH1 is the most important and widely expressed HH receptor, since its 
deficiency is embryonic lethal with phenotypes of ventralization and polydactyly 
and somatic loss-of-function mutations induce formation of medulloblastoma and 
basal cell carcinoma in mice and humans (9, 10). PTCH1 protein has 12-
transmembrane (TM) domains, cytosolic N- and C-terminal domains, and a large 
central cytosolic loop. The TM domains 4-6 encode a sterol sensing domain and 
the central region has homology with resistance-nodulation-division (RND) 
bacterial permeases. Both functional domains and the 12-TM “core” are necessary 
for inhibition of SMO in the absence of HH proteins. The PTCH1 CTD is 
dispensable for regulation of SMO (11); however, it is a critical regulatory domain 
responsible for the high turnover rate of PTCH1 (12, 13). The CTD binds to the 
ubiquitin E3 ligase Itch, which catalyzes ubiquitylation of K1426 to induce 
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endocytosis and degradation of PTCH1 (13). Limiting the expression level of 
PTCH1 is relevant because a region of the CTD adjacent to the Itch-binding PPXY 
site interacts with the adaptor proteins DRAL and TUCAN1 and induces the 
nucleation and activation of procaspase-9, leading to apoptotic cell death (14). This 
pro-apoptotic function of PTCH1, which has been classified as a “dependence 
receptor” because SHH prevents this negative signaling (15), belongs to the so 
called “non-canonical” HH signaling pathways, as it is independent of SMO and of 
the activity of the GLI transcription factors (13, 16). Thus, while the core 12-TM of 
PTCH1 functions in the regulation of canonical HH signaling, the CTD can regulate 
cell survival through other mediators.  
In this study, we sought to identify additional mediators of PTCH1 non-
canonical signaling by screening a cDNA library for specific interactions with the 
CTD. We found an unexpected interaction with an autophagy–specific protein. 
Autophagy is the process of the self-degradation of damaged organelles, 
cytoplasmic components and misfolded protein aggregates by segregation into a 
double membrane vesicle, the autophagosome, and fusion with lysosomes for 
proteolysis and lipolysis to take place (17, 18). The initiation of autophagy requires 
the unc51-like autophagy activating kinase (ULK) complex, which contains the 
Ser/Thr kinases ULK1 or ULK2, the autophagy-related protein 13 (ATG13), the 
FAK family kinase-interacting protein of 200 kDa (FIP200) and the autophagy-
related protein 101 (ATG101) (19). Nutrient starvation increases ULK kinase 
activity and causes phosphorylation of Beclin-1 and activation of the Vps34 subunit 
of an endomembrane-specific class III PI3K complex that generates 
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phosphatidylinositol-3-phosphate (PI3P) (20). PI3P triggers recruitment of the 
ATG12–ATG5–ATG16L1 complex to the extending phagophore membrane, 
where it lipidates LC3BI to generate the autophagosome membrane-bound 
LC3BII, a commonly used marker of autophagy (20, 21). LC3BII associates with 
the internal and external autophagosome membranes as the isolation membrane 
expands to form the autophagosome that engulfs a portion of the cytosol or 
selected cargo and organelles to be degraded (19). The last step in autophagy is 
the fusion of the autophagosome with lysosomes to form autolysosomes. After 
fusion, the contents of the autophagosome, including LC3BII, are degraded to 
generate biosynthetic building blocks and/or to eliminate damaged organelles or 
dangerous protein aggregates.  
Here, we report that in the absence of SHH, the CTD of PTCH1 interacts 
with the ULK complex through Atg101 and blocks completion of autophagy in a 
SMO-independent manner. We propose that the tumor suppressor function of 
PTCH1 relies on its regulation of the canonical Hh pathway as much as in the 
control of autophagy through CTD-dependent signaling.  
 
MATERIALS AND METHODS 
Reagents 
Recombinant Shh was synthesized, purified, and tested as previously described. 
KAAD-cyclopamine was purchased from EMD Millipore (Billerica, MA). 
Bafilomycin A1, chloroquine, doxycycline, and anti-b-actin antibody (AC-74) were 
from Sigma-Aldrich (St. Louis, MO). Antibodies targeting HA(C29F4), myc 
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(9B111), ATG101, p62, LC3B, FIP200, ULK1, phospho-ULK1(Ser757), ATG13, 
and GLI1 (L42B10) were from Cell Signaling Technology (Danvers, MA). 
Secondary anti-rabbit-HRP and anti-mouse-HRP antibodies were purchased from 
BioRad (Hercules, CA). Anti-GFP, secondary anti-rabbit-HRP and anti-mouse-
HRP Alexa 488 and Alexa 568 antibodies were from Invitrogen (Waltham, MA). 
 
Plasmids and adenoviral vectors 
PTCH1-HA, PTCH1DCTD-HA, PTCH1-myc, and myr-GFP-CTD1 encoding 
vectors were previously described (14). The myrGFP-CTD1 targets the fusion to 
the plasma membrane and endocytic vesicles. ATG101-RFP and HA-ATG101 (in 
PRK5 backbone) plasmids were a generous gift from Dr. Carol Mercer (University 
of Cincinnati, OH). AdV-PTCH1-HA was previously described (14). 
  
Cell Culture  
HEK 293, and HeLa cells were from American Type Tissue Collection (ATCC), 
Smo-/- MEFs were a gift from Dr. James Chen (Stanford University) and Ptc1-/- 
MEFs were a gift from Dr. Matthew Scott (Stanford University). Cells purchased 
from ATCC were not further authenticated, while the genotype of Smo-/-, Ptc1-/- and 
Ptc1+/- MEFs was verified by PCR. HEK293 and HeLa cells were used between 
passages 2-15 after thawing, while MEFs were used between 2-8 passages. Cells 
were tested for the presence of mycoplasma every 6 months by PCR analysis of 
conditioned medium of high density cultures. To generate SmoM2 cells in the Smo-
/- background, Smo-/- MEFs were transfected with SmoM2 cloned into pcDNA3.1-
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hygro or with empty plasmid by the calcium phosphate method. Cells were 
selected with hygromycin and expression of SmoM2 was confirmed by western 
blot, as previously described (22). All cells were cultured in Dulbecco's modified 
Eagle medium with 10% fetal bovine serum (Life Technologies), 100 U/ml 
penicillin, and 100 μg/ml streptomycin and maintained in a humidified 37 °C 
incubator at 5% CO2.  
HEK 293, HeLa, and Ptc1-/- MEFs cells were transfected using Lipofectamine 2000 
(Life Technologies, Camarillo, CA), following the manufacturers' instructions. Smo-
/- and SmoM2 MEFs were transduced with adenoviral particles.  
 
Yeast Two-Hybrid Analysis 
The yeast two-hybrid screening was carried out by Creative BioLabs using the 
Matchmaker Gold Yeast Two-Hybrid System (Clontech). The bait construct for 
yeast two-hybrid screening was made by subcloning the cDNA encoding 
NM_008957 (PTCH1 3469-4305 (278AA)) into the vector pGBKT7 (Clontech). The 
bait construct was transformed into the strain Y2HGold (MATa, trp1-901, leu2- 3, 
112, ura3-52, his3-200, gal4D, gal80D , LYS2 : : GAL1
UAS
-Gal1
TATA
-His3, GAL2
UAS
-
Gal2
TATA
-Ade2 URA3 : : MEL1
UAS
-Mel1
TATA AUR1-C MEL1) using standard 
procedures. The absence of autoactivation of the bait construct was verified by 
plating transformed yeast on minimal medium lacking the tryptophan and 
supplemented with X-a-galactosidase and Aureobasidin A. In the yeast two-hybrid 
screening, the bait was mated with Mouse Embryo 17-day Mate & Plate library 
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(Clontech) into Y187 strain. In total, 7x106
 
hybrids were screened. The potential 
positive hybrids were tested for His and Ade activation by co-transformation into 
the Y2HGold yeast strain. 23 positive clones showed His/Ade activation. The 
identity of the positive interactors was determined by sequencing.  
 
RNA interference 
Silencer select negative control siRNA #1 (#4390843), ATG101 siRNA-1 
(#s34253) (sense 5’-ACUUCAUCGACUUCACUUAtt-3’; antisense 
UAAGUGAAGUCGAUGAAGUca), ATG101 siRNA-2 (#s34254) (sense 5’-
CAGCCCUACCUGUACAAGAtt -3’; antisense UCUUGUACAGGUAGGGCUGca) 
were purchased from Ambion. Transfection was performed using 100nM of siRNA 
for HEK 293 cells, or 3nM for HeLa cells, using HiPerFect transfection reagent 
(Qiagen) according to the manufacturer’s protocol.  
 
Detection of autophagic markers by western blotting 
Cells were seeded in 6-well plates transfected or virally transduced as indicated 
above. At the end of the experiment, the culture medium was removed, cells were 
washed once in ice-cold PBS, and directly lysed in 100 µl of 1X Laemmli buffer 
(2% sodium dodecyl sulfate, 10% glycerol, 5% 2-mercartoethanol, 0.002% 
bromphenol blue and 62.5 mM Tris HCl, pH 6.8) to recover all soluble and insoluble 
material. Whole cell lysates were then sonicated for 15 sec, heated 5 min at 95°C, 
and used immediately or stored at -20°C for up to 5 days. Samples were separated 
in 15% SDS-PAGE gels, transferred onto nitrocellulose membranes at 50V for 2 
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h, and probed with anti-LC3B, p62 and b-actin antibodies at 1:1,000 dilution, 
followed by HRP-conjugated-secondary antibodies at 1:2,000 dilution. 
 
Immunoprecipitation  
For immunoprecipitation (IP) or co-immunoprecipitation (co-IP), cells were lysed in 
IP lysis buffer (50 mM Tris, pH 7.5, 150 mM Nacl, 1% NP-40, 1 mM EDTA, 1 mM 
EGTA, 2.5 mM MgCl2, 0.5% sodium deoxycholate, 1 mM DTT supplemented with 
protease inhibitors) for 30 min at 4°C. The lysate was cleared by centrifugation at 
4°C. Antibodies were added as recommended by the manufacturer for 2 h, 
followed by incubation with protein-A Dynabeads (Invitrogen) for 1 h at 4°C. After 
three washes in lysis buffer, proteins were eluted in Laemmli buffer for Western 
Blot. Densitometric quantifications of protein were determined using Image J 
software and normalized to total protein loading. 
 
Immunofluorescence 
Cells were cultured and transfected on Lab-Tek II chamber slides. Cells were fixed 
for 15 min in 4% formaldehyde, washed with phosphate buffered saline (PBS) 3 
times, and incubated in blocking buffer (PBS, 5% goat serum, 0.1% saponin) for 
1h at room temperature. Primary antibody was diluted in antibody solution (PBS, 
1% BSA, 0.1% saponin) and incubated at 4C overnight. After washed with PBS 3 
times, cells were incubated with secondary antibody conjugated with Alexa Fluor 
488 or 568 (Invitrogen) for 1h at room temperature. After PBS wash, the slides 
were mounted with Prolong Gold Antifade reagent. The immunofluorescent 
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pictures were taken by the Zeiss LSM510 Meta Confocal Laser Scanning 
Microscope or Nikon Eclipse E800, and analyzed by the LSM image browser or 
Nikon NIS Elements BR 3.0 software.  
 
Live cell imaging 
HEK 293 cells were infected with BacMam 2.0 RFP-GFP-LC3B (Invitrogen) for 24 
hours followed by transfection with pcDNA3.1 or PTCH1-HA plasmids as 
described above. After 24 h, red and green LC3B+ vesicles were imaged and 
quantified by using a Nikon Spinning Disk Confocal Microscope and MetaMorph 
Premier image acquisition and analysis software. The percentage of red vesicles 
over red + green vesicles (representing % autolysosomes) was quantified in 5 
different fields in 3 independent experiments. 
 
Gli-luciferase assay. Ptc1-/- MEFs were seeded in 24-well plates and transfected 
on the following day when they were at ?70% confluence. PTCH1-HA or empty 
vector, p8XGli-Luc, and pRL-TK were transfected at a ratio of 4:1:0.1 using the 
Fugene HD reagent according to the manufacturer's protocol. When cells reached 
100% confluence, typically between 24 and 48 h after transfection, the medium 
was changed to 0.5% serum for an additional 24 h, and 0.5 µM KAAD-cyclopamine 
added to some of the wells transfected with pcDNA3.1. Luciferase activity was 
determined with the Dual-Luciferase Reporter Assay System (Promega) using a 
Promega Glomax 20/20 luminometer, following the manufacturer's directions. 
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Quantitative PCR. Total RNA was isolated from cells using the RNeasy kit 
(Qiagen, Valencia, CA) as directed. cDNA was synthesized using the High 
Capacity cDNA Reverse Transcription kit (Applied BioSystems). Quantitative PCR 
of p62 and MAP1 LC3B was carried out using SsoFast EvaGreen Supermix 
(BioRad) and normalized to GAPDH. Primer sequences were as follows: GAPDH 
forward: 5’-CCCATCACCATCTTCCAGGAGCGA-3’, reverse 5’-
TCCACCCTTCAAGTGGGCCCC-3’; MAP1 LC3B forward 5’-
AGCAGCATCCAACCAAAATC-3’, reverse 5’-CTGTGTCCGTTCACCAACAG-3’ 
(23); p62(SQSTM1) forward 5’-ATCGGAGGATCCGAGTGT-3’, reverse 5’-
TGGCTGTGAGCTGCTCTT-3’ (24). Data were analyzed by the 2^DDCt method. 
 
Statistics. Densitometry of the protein levels on Western blots was performed 
using ImageJ software. Results were analyzed by a paired t test or by one-way 
analysis of variance, followed by Tukey's post hoc comparison or by a paired 
Student's t test, using GraphPad Prism (version 5.0) software 
 
RESULTS 
 
The C-terminal domain of Patched1 interacts with the autophagy protein 
ATG101.  We used the yeast-two-hybrid technique to identify novel proteins that 
are able to physically interact with the CTD of PTCH1, which we reported 
previously influences cell survival independently of the canonical Hh pathway and 
is dispensable for repression of SMO. The CTD of PTCH1 was fused to the GAL4 
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DNA-binding domain and used as bait to screen a mouse embryo E17 cDNA 
library cloned as fusions to GAL4-activator domain (prey). One of the 
complementing plasmids encoded a large fragment of Atg101(1-167), a 
mammalian-specific subunit of the ULK complex. Atg101 is almost entirely 
comprised of a single highly-structured Hop1, Rev7, Mad2 (HORMA) domain (1-
198), followed by a short unstructured “safety belt” (199-218), which in other 
HORMA domain-containing proteins like Mad2 allows a switch between open and 
closed conformations (25, 26). Thus, almost the complete HORMA domain of 
Atg101 was able to interact with the CTD of PTCH1 in yeast (Fig. 1A). This 
interaction was confirmed in HEK 293 cells by coimmunoprecipitation of a plasma 
membrane-targeted CTD fused to GFP (myr-GFP-CTD1) and hemagglutinin (HA)-
tagged ATG101 (Fig. 1B). The use of myristoylated GFP-CTD1 ruled out that the 
interaction the result of mislocalized CTD expression. The ability of full-length 
PTCH1 to interact with ATG101 was also confirmed by co-immunoprecipitation of 
myc-PTCH1 with HA-ATG101 (Fig. 1C). Confocal microscopy showed that co-
expressed PTCH1-eGFP and ATG101-RFP have a large degree of colocalization, 
in agreement with the biochemical studies (Fig. 1D). 
 
Patched1 interacts with the ULK complex through ATG101 HORMA domain. 
ATG101 is part of a >3 MDa complex containing ULK1/2, FIP200, and ATG13 that 
senses nutrient availability for the control of autophagy. Immunoprecipitation of 
PTCH1 was able to pulldown not only endogenous ATG101, but also the entire 
ULK complex in HEK293 (Fig. 2A) and HeLa cells (Fig. 2B). To investigate if 
 13 
interaction of PTCH1 with the ULK complex was mediated by ATG101, we silenced 
ATG101 expression by siRNA. As shown in Fig. 2C, a reduction in ATG101 protein 
level of ~90% caused a strong reduction of associated ATG101, ATG13, and 
ULK1. Unexpectedly, FIP200 interaction was retained in Atg101 depleted cells, 
albeit at a lower level. FIP200 is a large coiled-coil protein that interacts with many 
different partners and our data suggests that it could associate with full length 
PTCH1 via an unknown domain. In summary, these findings demonstrate that 
PTCH1 is able to interact with the endogenous ULK autophagy initiation complex 
via the ATG101 HORMA domain, and possible through FIP200, suggesting a 
regulatory function on autophagy or nutrient sensing. 
 
Patched1 inhibits basal and nutrient starvation-induced autophagy. We next 
sought to determine whether the interaction between PTCH1 and ATG101 has a 
functional consequence on autophagy. Autophagic flux is a dynamic process that 
describes the formation of autophagosomes containing cargo, their fusion with 
lysosomes, and final degradation of their content in the acidic environment of the 
autolysosomes. During initiation of autophagy, LC3BI is conjugated to 
phosphatidylethanolamine to from LC3BII, which marks autophagosome 
membranes. The internal membrane pool of LC3BII anchors adaptor proteins, 
such as p62, which link the cargo for degradation to the autophagosome lumen. 
After autolysosome formation, the internal pool of LC3BII and p62 are both 
degraded along with the cargo. Thus, during autophagy, LC3BII levels first 
increase and then decrease rapidly, while p62 levels only decrease. Measurement 
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of the relative levels of those two markers at different time points serves as a 
surrogate of “autophagic flux”. A useful tool for the study of autophagic flux are the 
drugs bafilomycin A1 and chloroquine that act by interfering with lysosomal fusion 
and acidification, increasing LC3BII and p62 levels. Overexpression of PTCH1 in 
cells growing in complete medium increased the level of LC3BII and p62, 
suggesting a similar mode of action to bafilomycin A1 (Fig. 3A and 3B). 
Interestingly, LC3BI levels were also elevated in PTCH1-expressing cells (1.9 ± 
0.2-fold, P<0.05), further supporting the notion that its degradation could be 
blocked. We ruled out that the increase of these markers was due to increased 
transcription because p62 and LC3B mRNA levels in PTCH1-HA-transfected cells 
were reduced by 24% and 55 %, respectively, as determined by qPCR (Fig. 1S). 
Amino acid starvation in Earle’s balanced salt solution (EBSS) for 4 h induced 
autophagy, as seen by reduction of both LC3BII and p62 compared cells grown in 
complete media, but strikingly less efficiently in cells overexpressing PTCH1 (Fig. 
3A and 3C). If the accumulation of LC3BII and p62 by PTCH1 were the result to a 
blockage at a step downstream autophagosome formation, addition of bafilomycin 
A1 or chloroquine would not cause further accumulation, while they would increase 
the level of the same markers in control cells. As shown in Fig. 3C, neither 
bafilomycin A1 nor chloroquine increased LC3BII and p62 levels in PTCH1-
expressing cells. These findings suggest that PTCH1 overexpression in HEK 293 
or HeLa cells seems to block autophagic flux, in contradiction with a previous study 
(27). Therefore, we used the tandem eGFP-RFP-LC3B reporter assay as a second 
independent measure of autophagic flux. Expression of the eGFP-RFP-LC3B 
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reporter marks autophagosomes in green and red fluorescence, since they 
accumulate lipidated eGFP-RFP-LC3BII. However, as autophagy proceeds, 
autophagosomes fuse with lysosomes and the contents are acidified, leading to a 
strong selective decrease in GFP fluorescence. In this assay, overexpression of 
PTCH1 in complete growth medium statistically reduced the percentage of RFP-
only vesicles (autolysosomes) from 11.3 ± 2.7% to 4.3 ± 1.1% (Fig. 3D).  
In order to investigate the function of endogenous Patched1 in autophagy, we 
compared the autophagic flux under amino acid-starvation of mouse embryonic 
fibroblasts (MEFs) isolated from Ptc1-/- mice or Ptc1+/- littermates. While both 
genotypes expressed similar levels of p62 and LC3B, Ptc1-/- MEFs increased 
LC3BII and p62 levels to a significantly larger degree than Ptc1+/- MEFs after 
addition of bafilomycin A1 (Fig. 3E). In other words, Ptc1-/- cells are more sensitive 
to the inhibitory actions of bafilomycin A1 compared to Ptc1+/- cells, as expected if 
endogenous Ptc1 limited the rate of autophagy. In addition, expression of PTCH1-
HA in Ptc1-/- MEFs increased LC3BII and p62 levels (Fig. 3F). Altogether, these 
observations suggest that PTCH1, expressed ectopically or endogenously, 
reduces autophagic flux by reducing autolysosome formation or by preventing their 
acidification and, consequently, reducing cargo degradation.  
 
The CTD of Patched1 is necessary to inhibit autophagy. Since PTCH1 
associates with ATG101 through the CTD, we tested whether this domain was 
necessary for autophagy inhibition. Expression of a PTCH1 mutant lacking the 
entire C-tail (PTCH1DCTD) was unable to increase LC3BII and p62 levels (Fig. 
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4A). Quantification of LC3BII increase (Fig. 4B) and of p62 (Fig. 4C) revealed a 
~3-fold for full length PTCH1 (P<0.05) and less than 1.5-fold for the CTD-lacking 
protein (non-significant, P>0.1) demonstrating that the effect is mostly mediated 
by the CTD. Conversely, we tested if the isolated CTD was sufficient to block 
autophagic flux. Overexpression of the isolated CTD increased the levels of LC3BII 
and p62 in HeLa cells (Fig. 4D-F), but it did not affect the markers in HEK293 cells 
significantly (Fig. 2S). In summary, our results demonstrate that the CTD of PTCH1 
is necessary for the autophagic block phenotype.    
 
ATG101 depletion attenuates accumulation of LC3BII and p62 after PTCH1 
overexpression. Since the CTD of PTCH1 interacts with ATG101, we sought to 
determine if ATG101 was a necessary mediator of autophagic flux inhibition by 
PTCH1. Silencing of ATG101 with two different siRNA duplexes strongly reduced 
LC3BII and p62 increase by PTCH1, although not completely (Fig. 5A and B). 
While the findings can be explained by the well-known requirement of ATG101 for 
mammalian autophagy, it indicates that most of the autophagic phenotype of 
PTCH1 can be explained by its interaction with ATG101. Interestingly, PTCH1 
levels significantly increase when ATG101 gene expression is silenced (Fig. 5A), 
suggesting that PTCH1 might be degraded along with other cargoes during 
autophagy.  
 
Patched1 function in autophagy is independent of Smoothened. The CTD of 
PTCH1 is dispensable for canonical Hh signaling (12, 14). Therefore, the 
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requirement of the CTD for autophagic flux blockade suggests that this novel 
function of PTCH1 is independent of SMO regulation, i.e. through a type I non-
canonical pathway. To test this hypothesis, we compared the effect of PTCH1 in 
mouse cells deficient in Smoothened (Smo-/- MEFs), unable to signal through the 
canonical Hh pathway with the same cells rescued with a constitutively active Smo 
mutant (SmoM2). The basal expression of Gli1 is undetectable in Smo-/- MEFs and 
is maximal in SmoM2-expressing cells (Fig. 6A). Importantly, the SmoM2 mutant 
is insensitive to regulation by PTCH1, as seen by its failure to inhibit Gli1 
expression in those cells (Fig. 6A). Introduction of PTCH1 in SmoM2-expressing 
MEFs by adenoviral delivery resulted in an increased level of LC3BII and p62 (Fig. 
6B, C), demonstrating that repression of SMO by PTCH1 is not required to inhibit 
autophagic flux. As a second approach to demonstrate that SMO is not a mediator 
of PTCH1-induced autophagy inhibition, we compared the effect of PTCH1 
expression in HEK 293 cells cultured in the presence of vehicle or of KAAD-
cyclopamine, a specific SMO inhibitor. Although LC3BII and p62 levels tended to 
be higher after KAAD-cyclopamine treatment for 24 h, expression of PTCH1 
elicited a further increase comparable to the one in cells treated with vehicle (Fig. 
6D, E). Under the same experimental conditions, expression of PTCH1 or addition 
of KAAD-cyclopamine fully inhibited a Gli-luciferase reporter in Ptc1-/- MEFs (Fig. 
6F). These findings demonstrate that PTCH1 inhibits autophagic flux 
independently of modulation of the canonical Hh pathway. 
 
Sonic Hedgehog opposes autophagic flux blockade by PTCH1.  Binding of 
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SHH to PTCH1 activates the canonical HH pathway and inhibits PTCH1’s pro-
apoptotic activity, also mediated by the CTD (13, 14). Thus, we tested if SHH was 
also able to prevent autophagic blockage by the CTD of PTCH1 in HEK 293 cells. 
While PTCH1 alone increased LC3BII and p62, simultaneous expression of 
PTCH1 and SHH prevented the increase in both markers (Fig. 6G). It is worth 
noting that cells expressing SHH had lower PTCH1-HA protein levels (Fig. 6G), 
since SHH binding to PTCH1 increases its turnover rate (13) and PTCH1-HA is 
expressed at a constant rate from the CMV promoter of the pcDNA3.1 vector. In 
addition, a modest reduction in basal LC3BII and p62 levels was observed by 
expression of SHH alone (Fig. 6G), although given the magnitude of the effect, it 
did not reach statistical significance. Since SHH both inhibits PTCH1 and induces 
its degradation, we cannot distinguish if SHH inhibits PTCH1 autophagic function 
directly or indirectly by reducing its levels. However, this data demonstrates that 
the inhibitory effect of PTCH1 on autophagy is prevented by Hh ligands.  
 
DISCUSSION 
 The tumor suppressor role of PTCH1, the Hh proteins receptor, is exerted 
through regulation of several downstream targets. First and most critical, it 
represses the oncogene SMO and blocks induction of pro-survival and mitogenic 
Gli-target genes through the canonical Hh pathway. In this and in a previous study 
(14), we continue to identify novel functions of PTCH1 that oppose cell growth and 
survival and are independent of SMO. The CTD of PTCH1 is dispensable for 
repression of SMO, although it facilitates SMO activation by increasing PTCH1 
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turnover (13). The HECT domain-containing E3 ubiquitin ligase Itch binds to 
PTCH1 CTD and ubiquitylates K1413, inducing internalization and degradation 
(14).  A different region of PTCH1 CTD, N-terminal of K1413, binds a protein 
complex containing pro-caspase-9 and activates an extrinsic apoptotic cascade 
that results in cell death and is sensitive to inhibition by Shh (15). Here we find a 
novel function of the CTD of PTCH1 that is exerted through physical interaction 
with the ULK complex subunit ATG101. Unbiased yeast two-hybrid screening 
using PTCH1 CTD was used to identify the HORMA domain of ATG101, a 25 kDa 
protein essential for ULK complex activation in mammals that acts as a chaperone 
for ATG13 (25). Our study validated the interaction with full-length PTCH1, through 
the CTD, in normal and transformed mammalian cells. Remarkably, PTCH1 
interacts with all the proteins of the ULK complex (ULK1, ATG13, and FIP200) 
through its binding to ATG101. Downstream of the ULK complex, PTCH1 causes 
a reduction of the autophagic flux by a mechanism that resembles that of 
bafilomycin A1. Autophagic flux is a dynamic process that encompasses formation 
of phagophore membranes decorated with lipidated LC3B, closure into 
autophagosomes containing organelles and other cargo labelled with p62, fusion 
of the outer membrane of the autophagome with lysosomes, and degradation by 
acidic hydrolases of the autolysosomal contents. Thus, increases in LC3BII levels 
by western blot or imaging can be explained by increased lipidation (autophagy 
induction) or decreased clearance by a blockade at the last steps of the process 
(fusion or acidification). Previously it was reported that PTCH1 expression 
increased LC3BII levels, which was interpreted as an increased in autophagy (27). 
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We performed a series of controls to distinguish the two possibilities. First, 
blockade of autolysosomal acidification with bafilomycin A1 or chloroquine showed 
no difference in accumulated LCB3II in cells expressing PTCH1 vs. empty plasmid. 
Second, we used the tandem RFP-GFP-LC3B marker to distinguish acidic from 
neutral pH vesicles that reflects autolysosomes and autophagosomes, 
respectively, and observed a 75% reduction in acidic LC3B+ structures. Both sets 
of results indicate that PTCH1 causes a reduction of the autophagic flux at the step 
of fusion of autophagosomes with lysosomes or that it compromises their 
acidification. Our conclusions are supported by a previous report that Ptc1-/- MEFs, 
with constitutive Hh signalling, have an increased autophagic flux than wild type 
cells, as we confirmed in this study. In that report, the authors also show that 
stimulation of SMO downstream of PTCH1 increases autophagic flux, but did not 
evaluate the effect of activation of HH signalling by the physiological SHH ligand. 
Our study and that of Pampliega et al. suggest that SHH increases autophagy by 
a double mechanism requiring suppression of the autophagy block imposed by 
PTCH1 and activation of a pro-autophagic signal from SMO (28). 
 Upon activation, the ULK complex relocalizes to perinuclear membranes to 
stimulate the class III PI3K complex composed of Vps34, Vps15, Beclin, AMBRA1 
and other regulatory subunits. Production of phosphatidylinositol-3-phosphate is a 
critical signal for membrane nucleation during autophagosomes formation. The 
process of autolysosome formation involves the activity of two additional class III 
PI3K complexes, the UVRAG complex and the Rubicon complex. Their opposing 
activity promotes (UVRAG) and inhibits (Rubicon) fusion and completion of 
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autophagy (19; 29). PTCH1 could be acting on one of these complexes or perhaps 
directly preventing acidification. It has been proposed, based on homology to 
bacterial permeases of the resistance-nodulation-differentiation (RND) family, that 
PTCH1 might function as a transporter of small lipophilic compounds in exchange 
for H+ (30). Thus, it is plausible that PTCH1 opposes lysosomal acidification 
independently of its interaction with ATG101, as suggested by the residual p62 
accumulation in ATG101-depleted cells. 
 The biological relevance of our findings is in line with our knowledge of 
PTCH1 in cancer. First, PTCH1 expression is very low in the absence of Shh, since 
it is one of the principal GLI-target genes. Second, PTCH1 is a dependence 
receptor and if overexpressed in the absence of ligand it triggers caspase-9-
dependent apoptosis. Here we show that overexpression of PTCH1 in the absence 
of ligand also blocks autophagic flux and it does so through interaction with 
ATG101. All these functions of PTCH1 result in diminished fitness for cancer cells. 
Somatic Ptch1 mutations in basal cell carcinomas frequently result in premature 
truncation of the CTD, which have also been detected in endometrial, colorectal, 
and gastric adenocarcinomas (31, and Cancer Genome Atlas TGCA Database). 
We propose that premature truncation of the CTD enhances cancer cell survival 
by avoidance of PTCH1-induced apoptosis and autophagy blockade. Moreover, 
many epithelial cancers of the GI tract with upregulated Hh signalling but without 
PTCH1 mutations are addicted to high levels of Shh or Ihh, and it is tempting to 
speculate that in part this is due to the required constant inhibition of PTCH1 to 
restraint the pro-apoptotic and anti-autophagic signalling. It is not surprising, then, 
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that SMO inhibitors have failed in trials to prevent GI tract neoplasms progression. 
 Our findings also clearly demonstrate that this novel function of PTCH1 is 
independent of SMO and Gli-dependent transcription. However, some canonical 
Gli-target genes have been shown to regulate autophagy (27), suggesting that the 
Hh pathway is able to regulate autophagy in different manners: in the absence of 
ligand, PTCH1 actively represses autophagy through a non-canonical pathway 
mediated by ATG101, while, in the presence of Hh proteins, PTCH1 is inhibited 
and pro-autophagic target genes are induced downstream of SMO by activation of 
the GLI transcription factors. 
 In conclusion, we identify a novel function of the Hh receptor PTCH1 in the 
regulation of autophagy that is mediated by physical interaction of its CTD with the 
ULK complex through ATG101. Inhibition of autophagy by PTCH1 is not the result 
of SMO repression, and it supports the need for development of therapeutic 
biologicals that block binding of PTCH1 to Hh ligands to promote cancer cell death. 
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FIGURE LEGENDS 
 
Figure 1. The C-terminal domain of PTCH1 physically interacts with ATG101. A. 
Schematic representation of PTCH1 topological structure, with the cytoplasmic 
CTD in red and relevant modification sites. Yeast-two-hybrid complementation 
assay of pGBKT7-CTD1 or empty pGBKT7 with pGADT7-Atg101(1-167) in 
synthetically-defined (SD) medium without Leu and Trp (SD-LT) and in SD without 
Leu, Trp, His, and supplemented with Aureobasidin A (SD-LTHA). The backbone 
of pGBKT7 and pGADT7 encode Trp and Leu biosynthesis genes, respectively; 
but expression of His biosynthesis gene and AurA resistance is driven by GAL4-
responsive UAS promoters of different sequence. B. HEK 293 cells were 
transfected with HA-ATG101 and myr-GFP-CTD1 or empty myr-EGFP. After 24 h, 
cells were lysed and GFP was immunoprecipitated with an anti-GFP antibody, 
followed by analysis of HA-ATG101 in the IP and the total lysate (input). C. HEK 
293 cells were transfected with full length myc-PTCH1 and HA-Atg101. After 24 h, 
cells were lysed and PTCH1 was immunoprecipitated with an anti-myc antibody, 
followed by analysis of HA-ATG101 in the IP and the total lysate (input). D. Co-
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localization of PTCH1-eGFP (green) and RFP-ATG101 (red) in COS-1 cells. Scale 
bar = 20 mm. 
 
Figure 2. PTCH1 interacts with the ULK complex via ATG101. A. Analysis of 
endogenous levels of FIP200, ULK1, ATG13, and ATG101 in HA-
immunoprecipitates of HEK 293 cells transfected with HA-PTCH1 or empty 
plasmid in comparison to their expression level in whole cell lysates (WCL). B. 
Same as A but in HeLa cells. C. HEK 293 cells were transfected with and ATG101-
targeting siRNA duplex or with scramble siRNA. 24 h later empty pcDNA3.1 or 
PTCH1-HA encoding plasmid were transfected as described. Following additional 
24 h, cells were lysed and immunoprecipitation (IP) of PTCH1-HA was performed, 
followed by analysis of endogenous levels of FIP200, ULK1, ATG13, and ATG101 
in the IP and the WCL. All experiments were repeated at least 3 times. 
 
Figure 3. PTCH1 impairs completion of autophagy. A. Expression levels of p62 
and LC3B in HEK 293 cells transfected with pcDNA3.1 or PTCH1-HA and cultured 
24 h in complete growth medium or 20 h in complete medium followed by 4 h in 
minimal EBSS. B. Densitometric quantification of p62 and LC3BII western blot 
signals and normalized to b-actin in HEK 293 and HeLa cells transfected with 
empty plasmid or PTCH1-HA (n = 5; * P < 0.05. ** P < 0.001). C. Expression levels 
of p62 and LC3B in HEK 293 cells transfected with pcDNA3.1 or PTCH1-HA and 
cultured 24 h in complete growth medium, without or with addition of 100 nM 
Bafilomycin A1 (BafA1) or 10 µM chloroquine (CQ) during the last 4 h. 
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Representative experiment of n = 3. Densitometric quantification of LC3BII/b-actin 
is indicated under the blot, bold numbers correspond to PTCH1-HA 
overexpressing cells. D. Live imaging in the red and green channels of COS-1 cells 
expressing the tandem RFP-GFP-LC3B reporter and transfected with pcDNA3.1 
or PTCH1-HA. Numbers in the overlay images indicate the percentage of red-only 
vesicles (autolysosomes) over total (red and green plus red only) vesicles 
(autolysosomes plus autophagosomes), the difference is statistically significant 
(n=3, P<0.05, Student’s t-test). Vesicles were counted in at least 10 individual cells 
in three independent experiments. E. Expression levels of p62 and LC3B in Ptc1-
/- and Ptc1+/- MEFs after 4 h in EBSS without or with addition of 100 nM Bafilomycin 
A1 (BafA1). Representative experiment of n = 3. Densitometric quantification of 
LC3BII and p62 western blot signals normalized to b-actin in Ptc1-/- (black bars) 
and Ptc1+/- MEFs (gray bars) (n = 3; * P < 0.05). F. Expression levels of p62 and 
LC3B in Ptc1-/- MEFs transfected with pcDNA3.1 or PTCH1-HA and cultured 24 h 
in complete growth medium, without or with addition of 10 µM chloroquine (CQ) for 
the last 4 h. Representative experiment of n = 3. Densitometric quantification of 
LC3BII and p62 western blot signals normalized to b-actin in pcDNA3.1-
transfected (black bars) or PTCH1-HA transfected (gray bars) Ptc1-/- MEFs (n = 3; 
** P < 0.01; *** P<0.001). 
 
Figure 4. The CTD of PTCH1 is necessary for autophagic flux inhibition. A. 
Expression levels of p62 and LC3B in HEK 293 cells transfected with pcDNA3.1, 
PTCH1-HA, or PTCH1DCTD-HA, cultured 24 h in complete growth medium. B. 
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Densitometric quantification of LC3BII levels normalized to b-actin in cells 
transfected as in A (n = 3; * P < 0.05). C. Densitometric quantification of p62 levels 
normalized to b-actin in cells transfected as in A (n = 3; * P < 0.05). D. Expression 
levels of p62 and LC3B in HeLa cells transfected with pcDNA3.1, PTCH1-myc, 
CTD-HA or PTCH1-myc plus CTD-HA, cultured 24 h in complete growth medium. 
B. Densitometric quantification of LC3BII levels normalized to b-actin in cells 
transfected as in D (n = 3; * P < 0.05). C. Densitometric quantification of p62 levels 
normalized to b-actin in cells transfected as in D (n = 3; * P < 0.05). 
 
Figure 5. Silencing of ATG101 expression attenuates autophagic flux blockade by 
PTCH1. A. HEK 293 cells were transfected with 2 independent siRNA duplexes 
targeting Atg101 (Atg101-1 and Atg101-2) or with scramble siRNA. 24 h later 
empty pcDNA3.1 or PTCH1-HA encoding plasmid were transfected as described. 
After 24 h, cells were lysed and the levels of p62, LC3B, Atg101, PTCH1-HA and 
b-actin were determined by western blot. B. Densitometric quantification of p62 
levels in PTCH1-expressing cells over empty plasmid, for each siRNA condition 
(n=3; * P<0.05). C. Quantification of LC3BII levels in PTCH1-expressing cells over 
empty plasmid, for each siRNA condition (n=3; * P<0.05). 
 
Figure 6. PTCH1 blocks autophagy completion independently of Smoothened. A. 
Smo-/- MEFs stably transfected with empty plasmid (pcDNA) or a constitutively 
active mutant (SmoM2) were transduced with adenovirus encoding PTCH1-HA 
(AdV-PTCH1) or a control adenovirus (AdV-lacZ). Cells were allowed to grow to 
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confluency, the growth media was replaced by 0.5% FBS-containing DMEM for 24 
h, then lysed and the expression level of endogenous Gli1, HA-PTCH1, and b-
actin were determined by western blot. B. Smo-/- MEFs stably transfected with 
SmoM2 were transduced with AdV-PTCH1 or a control AdV-GFP and 24 h later 
lysed for western blot analysis of p62 and LC3B levels. C. Quantification of p62 
and LC3BII levels in cells treated as in B (n=3; * P<0.05). D. HEK 293 cells were 
transfected with empty plasmid or PTCH1-HA and 24 h later treated with 0.5 µM 
KAAD-cyclopamine (KAAD) or DMSO for additional 24 h. The level of p62 and 
LC3B expression was interrogated by western blot. E. Densitometric quantification 
of p62 and LC3BII levels normalized to b-actin in cells incubated in DMSO (black 
bars) or KAAD-cyclopamine (gray bars) as in D (n=3; * P <0.05). F. Ptc1-/- MEFs 
were transfected with empty plasmid or PTCH1-HA together with 8XGli-(Firefly) 
luciferase and TK-(Renilla) luciferase reporters. After reaching confluency, serum 
was reduced from 10% to 0.5% for 24 h and supplemented with 0.5 µM KAAD-
cyclopamine (KAAD-CP) or vehicle. Luciferase activities were determined using 
the Dual Luciferase Assay as described in Materials and Methods. Data are 
presented as percent inhibition of the control (n=3; * P< 0.0001 by ANOVA). G. 
HEK 293 cells were transfected with empty plasmid alone, PTCH1-HA, PTCH1-
HA and SHH, or SHH alone. After 24 h, the expression level of p62 and LC3B were 
evaluated by western blot (n=3). Densitometric quantification of the band 
intensities normalized to b-actin is indicated under the blots. 
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